Effect of Low-molecular-weight Heparin Calcium Combined with Dipyridamole in the Treatment of Deep Venous Thrombosis of Lower Extremity after Operation in Patients with Fracture of Lower Extremity
Objective To study the effect of low molecular weight heparin calcium (LMWHC) combined with dipyridamole in the treatment of deep venous thrombosis (DVT) in patients with lower extremity fracture. Methods From February2017 to April 2018, 64 patients with deep venous thrombosis of lower extremity were selected. All patients were divided into two groups according to the method of digital table: the reference group and the study group, 32 cases each. The control group treated with dipyridamole alone and those treated with low-molecular-weight heparin calcium and dipyridamole were used as the study group. The therapeutic effects and D-dimer, fibrinogen were compared between the two groups. The whole blood viscosity was high and the blood related indexes were high. Results The total effective rate of treatment in the reference group and the study group was 78.139.88, respectively, which was significantly lower than that in the control group (P<0.05). After treatment, the blood related indexes in the study group were better than those in the control group (P<0.05). Conclusion The combination of low molecular weight heparin calcium and dipyridamole in the treatment of postoperative deep venous thrombosis of lower extremity fracture patients can significantly improve the therapeutic effect and improve the blood indexes of the patients.
Fracture of lower extremityDeep vein thrombosis of lower extremityLow molecular weight heparin calciumDipyridamole
NETL
NSTL
维普
万方数据
